Abselion

Based in Cambridge, United Kingdom, Abselion develops automated analytical instruments and biological sensors for the rapid quantification of proteins and biomolecules. The company utilizes proprietary redox electrochemical detection technology to manufacture benchtop devices, such as the Amperia system, which replace traditional time-consuming assays in laboratory workflows. Operating on a business-to-business model, the enterprise sells laboratory hardware alongside proprietary single-use sensor cartridges to biopharmaceutical companies, biomanufacturing facilities, and academic research institutions. In December 2024, the organization secured £6.6 million in Series A funding led by M Ventures, with additional participation from the investment firm BioProcess 360 Partners. The corporate leadership team includes Chairman Dale Gordon, who guides the commercialization of their analytical tools for biologics, viral vectors, and gene therapy development. Abselion was originally founded as HexagonFab in 2018 by chief executive officer Ruizhi Wang.